PRTC vs. CRNX, AXSM, RARE, HCM, PBH, CORT, MRUS, BHVN, FOLD, and XENE
Should you be buying PureTech Health stock or one of its competitors? The main competitors of PureTech Health include Crinetics Pharmaceuticals (CRNX), Axsome Therapeutics (AXSM), Ultragenyx Pharmaceutical (RARE), HUTCHMED (HCM), Prestige Consumer Healthcare (PBH), Corcept Therapeutics (CORT), Merus (MRUS), Biohaven (BHVN), Amicus Therapeutics (FOLD), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical preparations" industry.
PureTech Health (NASDAQ:PRTC) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.
Crinetics Pharmaceuticals has a consensus target price of $62.50, indicating a potential upside of 39.79%. Given Crinetics Pharmaceuticals' higher possible upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than PureTech Health.
PureTech Health has higher earnings, but lower revenue than Crinetics Pharmaceuticals.
PureTech Health has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.
Crinetics Pharmaceuticals received 138 more outperform votes than PureTech Health when rated by MarketBeat users. Likewise, 67.76% of users gave Crinetics Pharmaceuticals an outperform vote while only 38.89% of users gave PureTech Health an outperform vote.
0.0% of PureTech Health shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by insiders. Comparatively, 6.0% of Crinetics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
PureTech Health has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -4,223.27%. PureTech Health's return on equity of 0.00% beat Crinetics Pharmaceuticals' return on equity.
In the previous week, Crinetics Pharmaceuticals had 13 more articles in the media than PureTech Health. MarketBeat recorded 15 mentions for Crinetics Pharmaceuticals and 2 mentions for PureTech Health. Crinetics Pharmaceuticals' average media sentiment score of 0.69 beat PureTech Health's score of 0.57 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.
Summary
Crinetics Pharmaceuticals beats PureTech Health on 10 of the 15 factors compared between the two stocks.
Get PureTech Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PureTech Health Competitors List
Related Companies and Tools
